Comparison
LL-37 vs. Plecanatid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
597562-32-8
467426-54-6
Molecular weight
4493.33 g/mol
1682 g/mol
Half-life
no data
no data
Sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESno data
Mechanism of action
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Plecanatid
Plecanatide is structurally analogous to the body's own uroguanylin and, like it, activates the GC-C receptor at the gut surface, raising cGMP and fluid secretion. Its pH-dependent activity shifts the effect toward the proximal small intestine.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
0
of which in humans
1
0
Effects recorded
4
2
Open conflicts
1
1
Documented adverse events
0
1
Legal status
Full entries
Frequently asked questions
- What is the difference between LL-37 and Plecanatid?
- LL-37 is classified as "Research other", while Plecanatid is classified as "Research other". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Plecanatid?
- The highest available evidence level is "Human trial" for LL-37 and "Human RCT" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Plecanatid in Germany and the United States?
- Germany: LL-37 — Research only, Plecanatid — Unapproved. United States: LL-37 — Research only, Plecanatid — Prescription. These are factual summaries with source and review date on the individual pages.